Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients

被引:24
|
作者
Klug, C
Wutzl, A
Kermer, C
Voracek, M
Kornek, G
Selzer, E
Glaser, C
Poeschl, PW
Millesi, W
Ewers, R
机构
[1] Med Univ Vienna, Vienna Gen Hosp, Dept Craniomaxillofacial & Oral Surg, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Psychol, Div Res Methods & Differential Psychol, Vienna, Austria
[3] Med Univ Vienna, Div Oncol, Dept Internal Med 1, A-1090 Vienna, Austria
[4] Med Univ Vienna, Dept Radiotherapy, Ctr Excellence Clin & Expt Oncol, A-1090 Vienna, Austria
[5] Hosp Lainz, Ludwig Boltzmann Inst Gerostomatol, Inst Oral & Maxillofacial Surg & Dent, Vienna, Austria
关键词
chemotherapy; concurrent; multimodal therapy; oral cancer; outcome; radiotherapy;
D O I
10.1016/j.ijom.2004.04.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
To analyse survival and locoregional control in patients with advanced oral and oropharyngeal squamous cell carcinoma (SCC) after multimodal therapy with preoperative radiochemotherapy (RCT) and radical surgery. We included in this analysis 222 patients who underwent multimodal therapy between 1990 and 2000. Eligible were patients with UICC disease stages II-IV (T2: 33.3%; T3: 12.6%; T4: 54.1%; NO: 45.9%; NI: 17.6%; N2: 33.3%; N3: 3.2%; stage 11: 21.1%; stage 111: 14.9%; stage IV: 64%). Patients received preoperative radiochemotheraq consisting of Mitomycin C (15-20 mg/m(2), day 1) plus 5-Fluorouracil (750 mg/m(2) /24 h-infusion, days 1-5) and concomitant radiotherapy for a total dose of 50 Gy. Radical locoregional en bloc-resection according to the pretherapeutic tumour extension was carried out in all patients. After a median surveillance period of 72.3 months (24-152 months), 131 patients (59%) were alive, and 91 (41%) patients died; 12 (5%) of them died postoperatively, 46 (21%) due to tumour recurrence, and 33 (15%) deaths were not directly related to the primary tumour. Overall survival probability was 76% after 2 years, and 62% after 5 years. Two- and 5-year local control probability were 88 and 81%, respectively. Regarding the high percentage of stage IV disease in the reported patients, the multimodal concept is an effective therapy offering excellent survival and local control probability.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [1] Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor
    Klug, C
    Wutzi, A
    Kermer, C
    Ploder, O
    Sulzbacher, I
    Selzer, E
    Voracek, M
    Oeckher, M
    Ewers, R
    Millesi, W
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 34 (03) : 262 - 267
  • [2] PREOPERATIVE RADIOCHEMOTHERAPY IN ORAL AND OROPHARYNGEAL CANCER
    DOBROWSKY, W
    DOBROWSKY, E
    STRASSL, H
    ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1987, 244 (05): : 322 - 322
  • [3] Preoperative radiochemotherapy in the treatment of advanced oral cancer: Outcome of 276 patients
    Klug, Clemens
    Berzaczy, Dominik
    Voracek, Martin
    Nell, Christina
    Ploder, Oliver
    Millesi, Werner
    Ewers, Rolf
    JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2009, 37 (06) : 344 - 347
  • [4] Survival impact of bowel resection in patients with FIGO stage II-IV ovarian cancer
    Wang, Qing-miao
    Xiao, Yao
    Liu, Yue-xi
    Wei, Xing
    Gu, Qiu-ying
    Hua, Linghu
    Liu, Bing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 14843 - 14852
  • [5] Neoadjuvant radiochemotherapy and radical resection for advanced squamous cell carcinoma of the oral cavity -: Outcome of 134 patients
    Eich, Hans Theodor
    Loeschcke, Michael
    Scheer, Martin
    Kocher, Martin
    Bongartz, Rudolf
    Wacker, Sidonie
    Zoeller, Joachim E.
    Mueller, Rolf-Peter
    STRAHLENTHERAPIE UND ONKOLOGIE, 2008, 184 (01) : 23 - 29
  • [6] Preoperative concurrent chemoradiotherapy for stages II-IV oral squamous cell carcinoma: a retrospective analysis and the future possibility of this treatment strategy
    Kirita, T.
    Yamanaka, Y.
    Imai, Y.
    Yamakawa, N.
    Aoki, K.
    Nakagawa, Y.
    Yagyuu, T.
    Hasegawa, M.
    INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2012, 41 (04) : 421 - 428
  • [7] Preoperative paclitaxel/carboplatin radiochemotherapy for stage III/IV resectable oral and oropharyngeal cancer: Seven-year follow-up of a phase II trial
    Eckardt, A.
    Sinikovic, B.
    Hofele, C.
    Bremer, M.
    Reuter, C.
    ONCOLOGY, 2007, 73 (3-4) : 198 - 203
  • [8] Effectiveness of radiochemotherapy on lymph node metastases in patients with stage IV oropharyngeal cancer
    Sapundzhiev, NR
    Barth, PJ
    Vacha, P
    Dünne, AA
    Moll, R
    Engenhart-Cabillic, R
    Werner, JA
    ORAL ONCOLOGY, 2004, 40 (10) : 1007 - 1016
  • [9] Clinicopathologic and molecular characterization of stages II-IV gastric cancer with Claudin 18.2 expression
    Kwak, Yoonjin
    Kim, Tae-Yong
    Nam, Soo Kyung
    Hwang, Hye Jung
    Han, Daeyoung
    Oh, Hyeon Jeong
    Kong, Seong-Ho
    Park, Do Joong
    Oh, Do-Youn
    Lee, Hyuk-Joon
    Im, Seock-Ah
    Yang, Han-Kwang
    Lee, Hye Seung
    ONCOLOGIST, 2024,
  • [10] Survival of patients with pancreatic cancer II-IV stages depending on the stage, regimen used in the first line.
    Novoselova, Kristina A.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    Storozhakova, Anna E.
    Popova, Irina L.
    Tikhanovskaya, Natalya Mikhailovna
    Ryadinskaya, Ludmila A.
    Lyanova, Aza A.
    Snezhko, Tatyana A.
    Kabanov, Sergey N.
    Zhuzhelenko, Irina A.
    Kalabanova, Elena Aleksandrovna
    Svetickaja, Jana V.
    Kornilova, Irina
    Samaneva, Nataliya
    Sergeeva, Marina M.
    Salamov, Georgy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)